# Ophthalmic and Topical Dosage Form New Animal Drugs; Orbifloxacin, Mometasone Furoate Monohydrate, and Posaconazole Suspension
> **Food and Drug Administration** · Final rule. · Published 2010-04-01 · Effective 2010-04-01 · 75 FR 16346
## Document
- **Document number:** 2010-7163
- **Category:** other
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 75 FR 16346
- **CFR reference:** 21 CFR 524
- **Publication date:** 2010-04-01
- **Effective date:** 2010-04-01
- **HHS docket:** Docket No. FDA-2010-N-0002
## Abstract

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Intervet, Inc. The NADA provides for the veterinary prescription use of a suspension containing orbifloxacin, mometasone furoate monohydrate, and posaconazole for the treatment of otitis externa in dogs.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2010/04/01/2010-7163/ophthalmic-and-topical-dosage-form-new-animal-drugs-orbifloxacin-mometasone-furoate-monohydrate-and)
---
*AI Analytics · CC0 1.0*